Machine learning in drug discovery: a review

S Dara, S Dhamercherla, SS Jadav, CHM Babu… - Artificial intelligence …, 2022 - Springer
This review provides the feasible literature on drug discovery through ML tools and
techniques that are enforced in every phase of drug development to accelerate the research …

Applications of machine learning in drug discovery and development

J Vamathevan, D Clark, P Czodrowski… - Nature reviews Drug …, 2019 - nature.com
Drug discovery and development pipelines are long, complex and depend on numerous
factors. Machine learning (ML) approaches provide a set of tools that can improve discovery …

Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy

F Skoulidis, JV Heymach - Nature Reviews Cancer, 2019 - nature.com
The impressive clinical activity of small-molecule receptor tyrosine kinase inhibitors for
oncogene-addicted subgroups of non-small-cell lung cancer (for example, those driven by …

Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor

K Freeman-Cook, RL Hoffman, N Miller, J Almaden… - Cancer cell, 2021 - cell.com
Summary The CDK4/6 inhibitor, palbociclib (PAL), significantly improves progression-free
survival in HR+/HER2− breast cancer when combined with anti-hormonals. We sought to …

[HTML][HTML] New approaches to SCLC therapy: from the laboratory to the clinic

JT Poirier, J George, TK Owonikoko, A Berns… - Journal of Thoracic …, 2020 - Elsevier
The outcomes of patients with SCLC have not yet been substantially impacted by the
revolution in precision oncology, primarily owing to a paucity of genetic alterations in …

SCLC-CellMiner: a resource for small cell lung cancer cell line genomics and pharmacology based on genomic signatures

C Tlemsani, L Pongor, F Elloumi, L Girard, KE Huffman… - Cell reports, 2020 - cell.com
Summary CellMiner-SCLC (https://discover. nci. nih. gov/SclcCellMinerCDB/) integrates
drug sensitivity and genomic data, including high-resolution methylome and transcriptome …

A pharmacogenomic landscape in human liver cancers

Z Qiu, H Li, Z Zhang, Z Zhu, S He, X Wang, P Wang… - Cancer Cell, 2019 - cell.com
Liver cancers are highly heterogeneous with poor prognosis and drug response. A better
understanding between genetic alterations and drug responses would facilitate precision …

Exploring new targets and chemical space with affinity selection-mass spectrometry

R Prudent, DA Annis, PJ Dandliker… - Nature Reviews …, 2021 - nature.com
Affinity selection-mass spectrometry (AS-MS) is a high-throughput screening (HTS)
technique for drug discovery that enables rapid screening of large collections of compounds …

The evolution of cyber resilience frameworks in network security: a conceptual analysis

MO Akinsanya, CC Ekechi, CD Okeke - Computer Science & IT Research …, 2024 - fepbl.com
Abstract The Evolution of Cyber Resilience Frameworks in Network Security: A Conceptual
Analysis provides a comprehensive overview of the development and application of cyber …

Molecular determinants of nephron vascular specialization in the kidney

DM Barry, EA McMillan, B Kunar, R Lis, T Zhang… - Nature …, 2019 - nature.com
Although kidney parenchymal tissue can be generated in vitro, reconstructing the complex
vasculature of the kidney remains a daunting task. The molecular pathways that specify and …